{'fraction_non_alphanumeric': 0.023323615160349854, 'fraction_numerical': 0.013119533527696793, 'mean_word_length': 5.1891891891891895, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
F-18 FDG PET/CT imaging in small cell prostate cancer.

Abstract: Positron emission tomography/computed tomography scan with F-18 fluorodeoxyglucose was performed in a 77-year-old patient with prostatic adenocarcinoma treated with hormonal therapy, who presented 2 years later with an abdominal mass and slowly increasing prostate specific antigen and carcinoembryonic antigen. Positron emission tomography-computed tomography scan showed intense uptake of F-18 fluorodeoxyglucose in the prostate tumor, iliac, and periaortic lymph nodes and also in a focal area in the right lobe of the liver. The new biopsy of the tumor and lymph nodes was compatible with small cell prostate cancer.